Country: Írland
Tungumál: enska
Heimild: HPRA (Health Products Regulatory Authority)
SALICYLIC ACID
Alliance Pharmaceuticals Ltd.
17 %w/w
Cutaneous Solution
2004-04-19
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Occlusal (Low Strength) 17% w/w Cutaneous Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Salicylic Acid 17% w/w For excipients, see 6.1. 3 PHARMACEUTICAL FORM Cutaneous solution. Colourless to pale yellow solution with a characteristic smell of nail varnish. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Occlusal is indicated for the treatment and removal of common and plantar warts (verrucae). 4.2 POSOLOGY AND METHOD OF ADMINSTRATION For topical application. Prior to application soak wart in warm water for five minutes. Remove loose tissue with a brush, emery board, pumice or abrasive sponge, being careful to avoid causing pin-point bleeding or abrading the surrounding healthy skin. Dry thoroughly with a towel not used by others to avoid contagion. Carefully apply Occlusal twice to the wart using the brush applicator allowing the first application to dry before applying the second. Thereafter repeat treatment once daily or as directed by physician. Do not apply to surrounding healthy skin. Clinically visible improvement should occur in one to two weeks but maximum effect may be expected after four to six weeks. There are no differences in dosage for children, adults or the elderly 4.3 CONTRAINDICATIONS Occlusal should not be used by diabetics or patients with impaired blood circulation. Do not use on moles, birthmarks, unusual warts with hair growth, on facial warts, or in the anal or perineal region. 4.4 SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE Occlusal is for external use only. Do not permit contact with eyes or mucous membranes. If contact occurs flush with water for 15 minutes. Do not allow contact with normal skin around wart. Avoid using on areas of broken or damaged skin. Discontinue treatment if excessive irritation occurs. 4.5 Lestu allt skjalið